Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Glatirameracetat in der Darreichungsform Fertigpen, ATC L03AX13

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 05, 2027 · 219 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Glatirameracetat in der Darreichungsform Fertigpen, ATC L03AX13

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No estimated value or minimum guarantee provided. Revenue potential is unclear.

Open-house agreements automatically terminate if a nationally or regionally awarded discount contract for the same subs...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for Glatiramer acetate in pre-filled pen dosage form (ATC L03AX13).
  • Contracts are identical and non-negotiable for all pharmaceutical companies that meet eligibility criteria.
Afficher le résumé complet

Open-house model for non-exclusive discount agreements on Glatiramer acetate (pre-filled pen, ATC L03AX13) with AOK Bayern. All qualifying pharmaceutical companies can join identical, non-negotiable contracts. Contract period: 1 June 2025 to 31 May 2027, with possible later start. No estimated value provided.

Risques

No estimated value or minimum guarantee provided. Revenue potential is unclear.

Open-house agreements automatically terminate if a nationally or regionally awarded discount contract for the same subs...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer).

Administrative

  • Submit signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit signed contract and annex specifying the medicinal products.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; this is an open-house model where all eligible participants are accepted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Glatirameracetat in der Darreichungsform Fertigpen, ATC L03AX13

Single lot covering discount agreements for Glatiramer acetate pre-filled pen. Framework agreement with multiple contractors. Duration 24 months.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; this is an open-house model where all eligible participants are accepted.

Date limite

Deadline Apr 05, 2027

Détails de la procédure

Date de publication
15 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
249001-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30